Nordea Investment Management AB Acquires 12,470 Shares of LivaNova PLC (NASDAQ:LIVN)

Nordea Investment Management AB raised its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 22.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 68,711 shares of the company's stock after purchasing an additional 12,470 shares during the period. Nordea Investment Management AB owned approximately 0.13% of LivaNova worth $3,188,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Canada Pension Plan Investment Board acquired a new position in shares of LivaNova in the 2nd quarter valued at $88,000. Central Pacific Bank Trust Division acquired a new position in LivaNova in the third quarter valued at about $178,000. TradeLink Capital LLC bought a new stake in shares of LivaNova in the second quarter worth about $208,000. Captrust Financial Advisors acquired a new stake in shares of LivaNova during the third quarter worth about $217,000. Finally, Sanctuary Advisors LLC bought a new position in shares of LivaNova during the 3rd quarter valued at about $219,000. Institutional investors own 97.64% of the company's stock.

LivaNova Stock Down 2.9 %

NASDAQ:LIVN traded down $1.38 on Friday, hitting $46.66. 337,088 shares of the company's stock were exchanged, compared to its average volume of 368,231. The company has a market cap of $2.53 billion, a P/E ratio of 111.10 and a beta of 1.01. The firm has a 50-day moving average price of $49.82 and a 200-day moving average price of $50.34. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova PLC has a 52 week low of $43.15 and a 52 week high of $64.47.

Wall Street Analysts Forecast Growth

Several analysts have commented on LIVN shares. StockNews.com downgraded shares of LivaNova from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 25th. Needham & Company LLC restated a "buy" rating and set a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. The Goldman Sachs Group assumed coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 target price for the company. Robert W. Baird increased their target price on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, Baird R W upgraded LivaNova from a "hold" rating to a "strong-buy" rating in a report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, LivaNova has a consensus rating of "Buy" and an average price target of $69.17.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.27% of the company's stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.